Clinical Trials for Drug: MPDL3280A

2 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
UCI-16-90 A Phase III, Multicenter, Randomized Study Of Atezolizumab (Anti-PD-L1 Antibody) In Combination With Enzalutamide Versus Enzalutamide Alone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of An Androgen Synthesis Inhibitor And Failure Of, Ineligibility For, Or Refusal Of A Taxane Regimen Open
UCI-16-92 [WIRB] A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib versus Placebo plus Cobimetinib and Vemurafenib in Previously Untreated BRAF V600 Mutation-Positive Patients with Metastatic or Unresectable Locally Advanced Melanoma Open